Evidence map›Paper›PMID 33660119›Full record

ArticleJournal of neuro-oncology2021

Intracranial germ cells tumour: a single institution experience in Argentina.

Lorena V Baroni, Agustina Oller, Candela S Freytes, Claudia V Sampor, Natalia Pinto, Nicolas Ponce Fernandez, Carlos Rugilo, Fabiana Lubieniecki, Pedro Zubizarreta, Daniel Alderete

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Diencephalic syndrome in a female child due to intracranial germinoma: a case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lorena V Baroni *Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. lorelein@msn.com.ORCID http://orcid.org/0000-0002-1599-7080
Agustina Oller *Service of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. agustinaoller@gmail.com.ORCID http://orcid.org/0000-0001-8183-3167
Candela S FreytesService of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina.
Claudia V SamporService of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina.
Natalia PintoService of Radiotherapy, Hospital JP Garrahan, Buenos Aires, Argentina.
Nicolas Ponce FernandezService of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina.
Carlos RugiloService of Diagnostic Imaging, Hospital JP Garrahan, Buenos Aires, Argentina.
Fabiana LubienieckiService of Pathology, Hospital JP Garrahan, Buenos Aires, Argentina.
Pedro ZubizarretaService of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina.
Daniel AldereteService of Hematology/Oncology, Hospital JP Garrahan, 1881 Combate de los Pozos Street, Buenos Aires, Argentina. Danalder09@gmail.com.
Garrahan Hospital · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntracranial germ cell tumor (iGCT) represents a rare and heterogeneous group, with variable incidence and diverse treatment strategies. Although multiagent chemotherapy with reduced radiotherapy strategy has been applied by several cooperative groups in North America and Western Europe, there is a paucity of data to understand if this combined regimen is suitable in low-middle income countries (LMIC).

methodsWe evaluate the outcome in a cohort of iGCT treated by SIOP-CNS-GCT-96 strategy at hospital J.P Garrahan in Argentina over the last 20 years. Radiation field and dose included focal radiotherapy (FRT) before 2009 or focal radiotherapy plus whole ventricular radiotherapy (WVRT) after 2009 for localized germinoma and FRT or FRT plus WVRT or CSI for non germinomatous germ cell tumors (NGGCT)

resultsSixty iGCT were identified; 39 germinoma and 21 NGGCT. Median follow-up was 6.57 years (range 0.13-20.5). 5-year PFS and OS were 83.5% (95% CI [165.53-223.2]) and 88.7% (95% CI [169.84-223.2]) for the germinoma group, while for the NGGCT group were 75% (95% CI [133.27-219.96]) and 64.2% (95% CI [107.38-201.81]) respectively. The localized germinoma group showed poor results between 2000 and 2009 with 5-year PFS and OS of 69 and 75% respectively, and an excellent outcome between 2010 and 2019 with a 5-years PFS and OS of 92.8 and 100%. A univariable analysis identified this difference in survival as related to the field of radiotherapy, specifically whole ventricular radiotherapy. FRT increased the risk of recurrence in localized germinoma, involving not only ventricular relapses; but spinal cord and disseminated disease as well. There were no relapses of localized NGGCT after FRT and FRT plus WVRT.

conclusionHerein we demonstrate that intensive chemotherapy followed by FRT plus WVRT for germinoma is a feasible and effective strategy, warranting further study in the developing world.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsArgentinaBrain NeoplasmsChemotherapy, AdjuvantChildCranial IrradiationFemaleHumansMaleNeoadjuvant TherapyNeoplasms, Germ Cell and EmbryonalRadiotherapyRetrospective StudiesBrain tumorGerm-cell tumorGerminomaNon germinomatousReduced radiation field

Identifiers

PMID33660119
OpenAlexW3126594929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.